Analysts Are Optimistic We'll See A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA) [Yahoo! Finance]
Akebia Therapeutics (NASDAQ:AKBA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $5.00 price target on the stock.
Akebia Therapeutics (NASDAQ:AKBA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Announces Establishment of Rare Kidney Disease Pipeline